Dr. Erika P. Hamilton on the Shifting Treatment Paradigm in HER2-Positive Breast Cancer
Erika P. Hamilton, MD, discusses the current treatment paradigm, and upcoming treatments, for HER2-positive breast cancer.
Erika P. Hamilton , MD, associate director, Breast Cancer and Gynecologic Cancer Research Program, principal investigator, Sarah Cannon Research Institute, discusses the current treatment paradigm, and upcoming treatments, for HER2-positive breast cancer. She cites the approval of drugs like pertuzumab and T-DM1 over the years as a step in the right direction for treatment of HER2-positive breast cancer, and goes on to say that oncologists have more of an option in treatment now than ever before.
Hamilton says the biggest challenge oncologists face now is figuring out where to place these drugs in the treatment paradigm. She says as T-DM1 and pertuzumab are used more in the neoadjuvant or adjuvant space, the metastatic sequence may be up in the air more.
Therapy Type and Site of Metastases Factor into HR+, HER2+ mBC Treatment
December 20th 2024During a Case-Based Roundtable® event, Ian Krop, MD, and participants discussed considerations affecting first- and second-line treatment of metastatic HER2-positive breast cancer in the first article of a 2-part series.
Read More
Imlunestrant Improves PFS in ESR1-Mutant Advanced Breast Cancer
December 13th 2024The phase 3 EMBER-3 trial showed imlunestrant improved PFS over SOC endocrine therapy in ER-positive, HER2-negative advanced breast cancer with ESR1 mutations, though not significantly in the overall population.
Read More
